When: Confirmed close above $1,206 on volume >3.5M with MACD line cross above zero

Then: Invalidates topping pattern; potential upgrade to Overweight

HOLD with no new exposure above $1,150. Existing positions held. Accumulation zone $1,073-$1,150 with stop at $1,073. Trim levels at $1,198-$1,206 on strength without clean breakout.

• PEG ratio of 1.12 prices in 32% revenue CAGR and 51% EPS CAGR indefinitely
• Forward EPS target of $47.59 requires ~60% earnings growth from a base of nearly $65 billion in revenue
• If growth normalizes to 25% rather than 50% EPS growth, stock is priced for disappointment and multiple compression
• TTM FCF hit $11 billion and Q2 2026 OCF was $10.7 billion, but company took on $8.94 billion in new long-term debt in Q2 2026 alone
• Total debt rose $12.4 billion in six months; net debt is now $46 billion
• Working capital contracted by $3.5 billion, mechanically boosting OCF—this may not repeat in Q3 and Q4
• Supply constraints are leading indicator of supply glut risk in 2027-2028 when factory capacity comes online
• 40-50% of growth concentrated in two molecules in single therapeutic category is single point of failure risk
• 10-year and 30-year yields at highest levels since 2002
• Polymarket gives 1% probability of Fed cut by October 2026, 3% by December 2026
• Multiple compression risk on 40x trailing PE stock is convex if inflation prints hot and yields push to fresh highs
• MACD line still at negative 1.08 with bullish crossover occurring below zero
• Stock tested upper Bollinger Band at $1,198 and was sold into close; intraday high of $1,206 rejected
• Price closing below intraday high after testing resistance is distribution signal, not accumulation signal
• RSI at 58 climbing fast from 35 but approaching overbought territory
• Base case at $47.59 forward EPS and flat 25x multiple yields $1,189—exactly current price
• Aggressive case of 15% earnings beat gets to $1,368—not the base case
• Stock is fairly valued at current levels with roughly balanced upside and downside

→ vs aggressive: PEG ratio of 1.12 is not reasonable—it prices in unrealistic 51% EPS CAGR from a $65 billion revenue base, requiring ~60% earnings growth, which is hyper-growth not compounding

→ vs aggressive: FCF inflection is a single quarter's print; OCF of $10.7 billion was funded by $8.94 billion in new long-term debt and $3.5 billion working capital contraction that may not repeat

→ vs aggressive: Supply constraints are leading indicator of supply glut risk as Lilly, Novo, and competitors bring factory capacity online in 2027-2028, threatening pricing power

→ vs aggressive: 40-50% growth concentration in two molecules is a single point of failure, not a moat; orforglipron Phase 3 disappointment or competitor oral GLP-1 would create structural liability

→ vs aggressive: Higher inflation may increase political appetite for pharmaceutical price controls, not reduce it; reading balance sheet decisions as policy forecasts is a category error

→ vs aggressive: MACD crossover is occurring below zero; stock rejected at upper Bollinger Band and intraday high, showing distribution not accumulation

→ vs aggressive: Waiting for 10% pullback to $1,073 is not missing upside—the base case at $47.59 EPS and 25x multiple equals current price, meaning upside and downside are roughly balanced

→ vs neutral: The trader's plan correctly calls for Q3 and Q4 FCF validation before treating inflection as durable; treating single-quarter OCF as guaranteed trajectory is how investors get carried out at the top

→ vs neutral: The $1,198-$1,206 trim levels without clean breakout are appropriate given nascent MACD crossover and RSI approaching overbought

HOLD existing positions; no new exposure above $1,150; treat HOLD as the active thesis with explicit monitoring triggers

• To deliver $47.59 forward EPS from TTM EPS of $29.79, need 60% earnings growth against expanding revenue base
• LLY trading at 25x forward means market already discounting normalization; hyper-growth compounder thesis argues against current multiple, not for it
• Q2 2026 OCF of $10.7B is genuine; even shaving 30% for working capital tailwinds implies $7-8B core OCF and full-year run rate north of $25B
• Orforglipron Phase 3 readout is the single biggest binary event determining whether concentration is a moat or liability
• MACD crossover is real but nascent with MACD line still negative; momentum confirmation not yet established
• RSI recovered from 35 to 58; rejection at upper Bollinger Band at $1,198 with intraday high of $1,206 is warning sign
• Polymarket showing 1% probability of Fed cut by October 2026 and just 3% by December 2026; path of least resistance is yields stable to higher
• Asymmetry between aggressive and conservative arguments is 55-45 in favor of cautious view at current price
• Current stop at $1,073 (~7%) versus 4% upside to trim zone ($1,206) offers poor asymmetry; wider stop at $1,050-1,060 or tighter at $1,100 with partial trim recommended
• Higher for longer being priced in doesn't protect the multiple; 40x trailing PE has asymmetric downside if yields push higher

→ vs aggressive: PEG of 1.12 as 'reasonable' requires believing 32% revenue CAGR and 51% EPS CAGR continue at exact pace; base effect math is brutal and the hyper-growth startup framing actually argues against a 25x multiple, not for it

→ vs conservative: FCF inflection is genuine but magnitude overstated for 2026; Q2 2026 OCF of $10.7B is not a working capital mirage and core OCF still supports $25B+ annual run rate

→ vs conservative: MFN is a tail risk with rising but still uncertain probability; high inflation doesn't guarantee MFN, treating it as certainty is an overcorrection